GANX
Gain Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.25
−0.79%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -7.6%
- EBIT
- -11.8%
- EPS
- +24.2%
- Free cash flow
- -2.7%
- Operating cash flow
- -2.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +71.0%
- EPS
- -15.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +3.0%
- EBIT
- +8.1%
- Net income
- +1.2%
- EPS
- +31.5%
- Free cash flow
- +2.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026